Solar lentigo
Conditions
Interventions
Test product A group
Test product B group
Test product C group
Test product D group
Test product E group
Test product F group
Medical treatment group
Sponsors
Jieikai Byoin
POLA Chemical Industries Inc.
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: (1) Persons who have received an explanation of this study, understand it, and agree to participate in the study of their own free will (persons who have given their informed consent) (2) Persons who are aware that they have solar lentigo (3) Persons who are able to fill out the consent form and other documents (4) Persons who are able to come to the designated facility on the day of the study
Exclusion criteria
Exclusion criteria: (1) Persons who have skin symptoms such as external wound, rosacea, eczema, etc. at the evaluation site (2) Persons who regularly go or plan to go to tanning salons during the study period (3) Persons who are likely to be exposed to significant sunlight during the study period (e.g., Daily exercise during the daytime) (4) Persons with a history of atopic dermatitis (5) Persons who are expected to suffer from severe hay fever* during the study period (*level requiring a hospital visit) (6) Persons with a history of severe hepatic disorder, renal disorder, or myocardial infarction (7) Persons with severe anemia (8) Persons with a keloid constitution (scars easily become red and swollen and are difficult to heal) (9) Persons who have diabetes mellitus (10) Persons who are taking antithrombotic medicines (11) Pregnant, lactating mothers and those who plan to become pregnant during the study period (12) Persons who are currently participating in other clinical studies or who plan to participate in other clinical studies during the study period (13) Persons with cold symptoms or fever of 37.5 degrees Celsius or higher (Exclusion criteria only on the day of the visit; temperature will be checked at the reception desk) (14) Persons who are taking or have taken gold preparations (Shiosol, Auranofin,etc.) for rheumatism, etc (15) Persons who have gold threads or metal plates, etc. inserted in the treatment area (face) (16) Persons who have skin-colored tattoos on the treatment area (face) (17) Persons who have undergone cosmetic surgery in the past and are currently in downtime (18) Persons who have experienced severe pain, erythema, or scarring after undergoing cosmetic surgery in the past (19) Persons who have experienced rashes or skin problems due to hair dye (20) Others whom the doctors involved in the research deem inappropriate
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| # Analysis of relationship between skin color change and gene expression at each measurement point. # Differences in gene expression changes among treatments. | — |
Secondary
| Measure | Time frame |
|---|---|
| # Differences in gene expression between groups with and without improvement of solar lentigo. # Analysis of relationship between gene expression and hyperpigmentation except solar lentigo in the medical treatment group. | — |
Countries
Japan
Contacts
Public ContactFumiya Yamaji
POLA Chemical Industries,Inc. Frontier Research Center
Outcome results
None listed